Capstone Diagnostics / Provista Health — COVID-19 Testing Fraud
COVID Testing Labs Pay Over $40 Million for Kickback and Billing Fraud
Source: U.S. Department of Justice
TL;DR: COVID Testing Labs Pay Over $40 Million for Kickback and Billing Fraud This case resulted in a $40.6 Million resolution and demonstrates the impact of whistleblower protections in recovering funds from fraud.
Summary
In a DOJ-announced resolution involving Capstone Diagnostics, the lab owner pleaded guilty to a kickback conspiracy charge and, along with the laboratory, agreed to pay $14.3 million to resolve allegations that kickbacks and sales commissions drove medically unnecessary testing reimbursed by government healthcare programs. DOJ alleged one component involved paying to generate unnecessary urine drug testing tied to an at-risk youth program and Medicaid billing, and another component involved paying representatives during the COVID-19 pandemic to push expensive respiratory pathogen panels (RPPs) to senior communities seeking only COVID tests—allegedly using forged physician signatures and sham diagnosis codes to generate orders. Separately, DOJ reported default FCA judgments totaling about $26.3 million against Provista Health and related entities and their owner, alleging the defendants used COVID testing access at nursing homes as a vehicle to bill Medicare for medically unnecessary RPP testing, including claims without physician orders and claims for tests not performed (with some specimen-collection dates alleged to be after a beneficiary's death).
Our Take
COVID-testing cases involving add-on panels usually share a pattern: "COVID access" becomes the sales hook, and then high-dollar ancillary testing becomes the revenue engine. Inside organizations, the key evidence is operational: who filled out requisitions, how diagnoses were selected, whether ordering clinicians actually reviewed medical need, and how sales reps were paid. If you've seen RPP or toxicology volume spike without clinical justification, focus on incentives, documentation integrity, and the workflow that let orders be created at scale.
Read the full article from the original source:
View Original ArticleOpens in a new tab. Content from U.S. Department of Justice.
Notice
The summaries above are based on publicly available information released by the U.S. Department of Justice and are provided for informational purposes only. They do not constitute legal advice, investigative findings, or allegations by Disclosure Strategy. Our commentary reflects general, experience-based observations about how False Claims Act matters commonly arise and is not a statement about any party's liability.